Drugs and endogenous ligands compete for receptor occupancy.
Dietary and endogenous ligands compete with drugs for receptor occupancy and therefore should be considered during therapeutic interventions and during pharmacokinetic/pharmacodynamic modeling. When disease is the result of an overabundance of these natural ligands, antibodies and/or their Fab fragments may be useful as therapeutic agents to reverse the effects of the natural ligands.
Colburn
W A
WA
Harris Laboratories, Inc., Clinical Development Division, Phoenix, Arizona 85040.
D000906:Antibodies / Q000378:metabolism / Q000627:therapeutic use; D001667:Binding, Competitive; D004723:Endorphins / Q000378:metabolism; D004745:Enkephalins / Q000378:metabolism; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000378:metabolism; D008024:Ligands; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D011955:Receptors, Drug / Q000378:metabolism*; D018079:Receptors, GABA / Q000378:metabolism
D000906:Antibodies; D004723:Endorphins; D004745:Enkephalins; D007140:Immunoglobulin Fab Fragments; D008024:Ligands; D004364:Pharmaceutical Preparations; D011955:Receptors, Drug; D018079:Receptors, GABA